Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Bladder Cancer

  Free Subscription


1 Adv Nutr
1 Adv Radiat Oncol
1 Asian J Surg
2 Biomedicines
1 Biomolecules
1 BMC Cancer
1 BMJ Open
1 Br J Radiol
1 Cancer Lett
4 Cancers (Basel)
1 Chin Med J (Engl)
1 Clin Genitourin Cancer
1 Clin Med Insights Case Rep
1 Clin Pharmacol Ther
1 Clin Transl Med
1 Curr Cancer Drug Targets
1 Curr Oncol
1 Diagn Pathol
1 Discov Med
1 Ecotoxicol Environ Saf
1 Environ Toxicol
1 Eur J Clin Invest
1 Eur Radiol Exp
3 Eur Urol
1 Eur Urol Focus
1 Exp Ther Med
1 Expert Opin Pharmacother
1 Front Bioeng Biotechnol
1 Front Cell Dev Biol
2 Front Immunol
3 Front Oncol
1 Gan To Kagaku Ryoho
1 Genes (Basel)
1 Geroscience
2 Indian J Cancer
1 Insights Imaging
1 Int J Equity Health
2 Int J Mol Sci
2 Int J Surg Pathol
3 Int Urol Nephrol
1 J Biomol Struct Dyn
1 J Cancer Res Clin Oncol
1 J Exp Clin Cancer Res
1 J Magn Reson Imaging
1 J Urol
1 Medicine (Baltimore)
1 Metabolomics
1 Nat Med
1 Neoplasia
1 Neurol Res
2 Nihon Hinyokika Gakkai Zasshi
1 NPJ Precis Oncol
1 Pathol Res Pract
1 Pilot Feasibility Stud
2 Sci Rep
1 Tunis Med
1 Turk Patoloji Derg
1 Urol Int
3 Urol Oncol
2 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Adv Nutr

  1. DAI YN, Yi-Wen Yu E, Zeegers MP, Wesselius A, et al
    The Association between Dietary Inflammatory Potential and Urologic Cancers: A Meta-analysis.
    Adv Nutr. 2023 Nov 3:100124. doi: 10.1016/j.advnut.2023.
    PubMed         Abstract available

    Adv Radiat Oncol

  2. CHANG YC, Wu YY, Tsan DL, Yap WK, et al
    Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection.
    Adv Radiat Oncol. 2024;9:101302.
    PubMed         Abstract available

    Asian J Surg

  3. LIU H, Wang X, Wu G, Wu J, et al
    PRPF19 could serve as a prognostic biomarker for patients with bladder cancer: A comprehensive analysis by integrating bulk and single-cell sequencing.
    Asian J Surg. 2024 Jan 19:S1015-9584(24)00115.


  4. LIU J, Tian C, Qiao J, Deng K, et al
    m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148/DAB1 Axis.
    Biomedicines. 2024;12:114.
    PubMed         Abstract available

  5. TATSUTA T, Ito J, Yamamoto K, Sugawara S, et al
    Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer.
    Biomedicines. 2024;12:192.
    PubMed         Abstract available


  6. SUZUKI S, Gi M, Komiya M, Obikane A, et al
    Evaluation of the Mechanisms Involved in the Development of Bladder Toxicity following Exposure to Occupational Bladder Cancer Causative Chemicals Using DNA Adductome Analysis.
    Biomolecules. 2023;14:36.
    PubMed         Abstract available

    BMC Cancer

  7. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    PubMed         Abstract available

    BMJ Open

  8. WEN F, Lin T, Zhang P, Zeng H, et al
    Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial.
    BMJ Open. 2024;14:e076663.
    PubMed         Abstract available

    Br J Radiol

  9. CAI Q, Huang Y, Ling J, Kong L, et al
    Radiomics nomogram for predicting disease-free survival after partial resection or radical cystectomy in patients with bladder cancer.
    Br J Radiol. 2024;97:201-209.
    PubMed         Abstract available

    Cancer Lett

  10. FUKUSHIMA H, Takao S, Furusawa A, Valera Romero V, et al
    Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer.
    Cancer Lett. 2024 Jan 23:216606. doi: 10.1016/j.canlet.2023.216606.
    PubMed         Abstract available

    Cancers (Basel)

  11. UZELAC M, Xin R, Chen T, John D, et al
    Urinary Microbiome Dysbiosis and Immune Dysregulations as Potential Diagnostic Indicators of Bladder Cancer.
    Cancers (Basel). 2024;16:394.
    PubMed         Abstract available

  12. VERMA S, Swain D, Kushwaha PP, Brahmbhatt S, et al
    Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
    Cancers (Basel). 2024;16:246.
    PubMed         Abstract available

  13. MARTINS EP, Vieira de Castro J, Fontes R, Monteiro-Reis S, et al
    Relevance of HOTAIR rs920778 and rs12826786 Genetic Variants in Bladder Cancer Risk and Survival.
    Cancers (Basel). 2024;16:434.
    PubMed         Abstract available

  14. DESPONDS E, Croci D, Wosika V, Hadadi N, et al
    Immuno-Transcriptomic Profiling of Blood and Tumor Tissue Identifies Gene Signatures Associated with Immunotherapy Response in Metastatic Bladder Cancer.
    Cancers (Basel). 2024;16:433.
    PubMed         Abstract available

    Chin Med J (Engl)

  15. WU Y, Cai D, Fan J, Meng C, et al
    An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.
    Chin Med J (Engl). 2024;137:232-234.

    Clin Genitourin Cancer

  16. SAVIN Z, Mano R, Lazarovich A, Rosenzweig B, et al
    Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024 Jan 6:S1558-7673(24)00004.
    PubMed         Abstract available

    Clin Med Insights Case Rep

  17. TRUONG TH, Nguyen DH, Dinh KN, Thai MS, et al
    Urethral Recurrence After Cystectomy and Orthotopic Bladder Reconstruction: A Rare Case of Recurrent Bladder Cancer After 12 Years and Review of the Literature.
    Clin Med Insights Case Rep. 2024;17:11795476231224188.
    PubMed         Abstract available

    Clin Pharmacol Ther

  18. LI X, Zhang L, Hu S, Liu D, et al
    Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System.
    Clin Pharmacol Ther. 2024;115:256-268.
    PubMed         Abstract available

    Clin Transl Med

  19. OUYANG W, Xu R, Yao H, Jiang S, et al
    Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours.
    Clin Transl Med. 2024;14:e1549.

    Curr Cancer Drug Targets

  20. WAN S, Li KP, Wang CY, Yang JW, et al
    Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer.
    Curr Cancer Drug Targets. 2024 Jan 23. doi: 10.2174/0115680096272663231121100515
    PubMed         Abstract available

    Curr Oncol

  21. VOLBERG C, Urhahn F, Pedrosa Carrasco AJ, Morin A, et al
    End-of-Life Care Preferences of Patients with Advanced Urological Malignancies: An Explorative Survey Study at a Tertiary Referral Center.
    Curr Oncol. 2024;31:462-471.
    PubMed         Abstract available

    Diagn Pathol

  22. SU Z, Wei J, Yuan X
    Giant cell-rich solitary fibrous tumour of the urinary bladder: case report of an unusual histological variant and literature review.
    Diagn Pathol. 2024;19:20.
    PubMed         Abstract available

    Discov Med

  23. WANG K, Xiao W, Zeng Q
    Curcumin Inhibits Bladder Cancer by Inhibiting Invasion via AKT/MMP14 Pathway.
    Discov Med. 2024;36:71-81.
    PubMed         Abstract available

    Ecotoxicol Environ Saf

  24. SHI J, Zhang K, Xiao T, Yang J, et al
    Exposure to disinfection by-products and risk of cancer: A systematic review and dose-response meta-analysis.
    Ecotoxicol Environ Saf. 2024;270:115925.
    PubMed         Abstract available

    Environ Toxicol

  25. YANG J, Ji Z, Gao F, Wu J, et al
    Cigarette smoking combined with genetic variation regulates the m(6) A methylation of CRNKL1 and is associated with bladder cancer risk.
    Environ Toxicol. 2024 Jan 25. doi: 10.1002/tox.24138.
    PubMed         Abstract available

    Eur J Clin Invest

  26. COPUR S, Yildiz AB, Covic A, Kanbay M, et al
    Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
    Eur J Clin Invest. 2024;54:e14131.
    PubMed         Abstract available

    Eur Radiol Exp

  27. MESSINA E, Proietti F, Laschena L, Flammia RS, et al
    MRI for risk stratification of muscle invasion by upper tract urothelial carcinoma: a feasibility study.
    Eur Radiol Exp. 2024;8:9.
    PubMed         Abstract available

    Eur Urol

  28. POWLES T, Assaf ZJ, Degaonkar V, Grivas P, et al
    Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Eur Urol. 2024;85:114-122.
    PubMed         Abstract available

  29. SRIDHAR SS, Powles T, Climent Duran MA, Park SH, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Eur Urol. 2024;85:154-163.
    PubMed         Abstract available

  30. NAOUN N, Loriot Y
    Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
    Eur Urol. 2024;85:123-124.

    Eur Urol Focus

  31. MONTORSI F, Moschini M, Salonia A, Gandaglia G, et al
    Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized
    Eur Urol Focus. 2024 Jan 24:S2405-4569(24)00005.

    Exp Ther Med

  32. ZHAO C, Qi L, Chen M, Liu L, et al
    [Retracted] microRNA?195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription?3 signaling.
    Exp Ther Med. 2023;27:78.
    PubMed         Abstract available

    Expert Opin Pharmacother

  33. ABOU CHAKRA M, Packiam VT, Duquesne I, Peyromaure M, et al
    Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand Now?
    Expert Opin Pharmacother. 2024 Jan 24. doi: 10.1080/14656566.2024.2310073.
    PubMed         Abstract available

    Front Bioeng Biotechnol

  34. TAK S, Han G, Leem SH, Lee SY, et al
    Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis.
    Front Bioeng Biotechnol. 2024;11:1302983.
    PubMed         Abstract available

    Front Cell Dev Biol

  35. ENOMOTO T, Okada H, Tomita H, Iinuma K, et al
    Glycocalyx analysis of bladder cancer: three-dimensional images in electron microscopy and vicia villosa lectin as a marker for invasiveness in frozen sections.
    Front Cell Dev Biol. 2024;11:1308879.
    PubMed         Abstract available

    Front Immunol

  36. ALCANTARA MB, Tang WS, Wang D, Kaniowski D, et al
    Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
    Front Immunol. 2024;14:1274781.
    PubMed         Abstract available

  37. HUANG S, Huang Y, Li C, Liang Y, et al
    Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.
    Front Immunol. 2024;14:1332213.
    PubMed         Abstract available

    Front Oncol

  38. WANG W, Huang G, Lin H, Ren L, et al
    Corrigendum: Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis.
    Front Oncol. 2024;13:1216134.
    PubMed         Abstract available

  39. GARG H, Bhandari M, Dursun F, Liss MA, et al
    A comparative analysis of radical cystectomy with perioperative chemotherapy, chemoradiation therapy, or systemic therapy in patients with clinically advanced node-positive bladder cancer (cN2/N3).
    Front Oncol. 2024;13:1157880.
    PubMed         Abstract available

  40. WEN F, Lin T, Zhang P, Shen Y, et al
    RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Front Oncol. 2024;13:1233196.
    PubMed         Abstract available

    Gan To Kagaku Ryoho

  41. TOMIYAMA E, Fujita K, Nonomura N
    [?. Urinary Liquid Biopsy in Bladder Cancer- Current Status and Issues].
    Gan To Kagaku Ryoho. 2024;51:40-44.

    Genes (Basel)

  42. JEONG MS, Mun JY, Yang GE, Kim MH, et al
    Exploring the Relationship between CLPTM1L-MS2 Variants and Susceptibility to Bladder Cancer.
    Genes (Basel). 2023;15:50.
    PubMed         Abstract available


  43. WOOLBRIGHT BL, Xuan H, Ahmed I, Rajendran G, et al
    Aging induces changes in cancer formation and microbial content in a murine model of bladder cancer.
    Geroscience. 2024 Jan 25. doi: 10.1007/s11357-024-01064.
    PubMed         Abstract available

    Indian J Cancer

  44. SAHETIA KM, Dave VN, Pal M, Menon S, et al
    Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
    Indian J Cancer. 2023;60:575-577.
    PubMed         Abstract available

  45. COBAN G, Yildiz P, Sahin N, Ersoz C, et al
    CD47 expression in urothelial carcinoma and its correlation with histopathological findings.
    Indian J Cancer. 2023;60:458-463.
    PubMed         Abstract available

    Insights Imaging

  46. SUN R, Zhang M, Yang L, Yang S, et al
    Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study.
    Insights Imaging. 2024;15:21.
    PubMed         Abstract available

    Int J Equity Health

  47. MOUSAVIAN AH, Shafiee G, Sheidaei A, Balajam NZ, et al
    The 15-year national trends of urinary cancers incidence among Iranian men and women; 2005-2020.
    Int J Equity Health. 2024;23:13.
    PubMed         Abstract available

    Int J Mol Sci

  48. KOCHERGIN M, Fahmy O, Asimakopoulos A, Theil G, et al
    Photodynamic Therapy: Current Trends and Potential Future Role in the Treatment of Bladder Cancer.
    Int J Mol Sci. 2024;25:960.
    PubMed         Abstract available

  49. SHAN KS, Dalal S, Thaw Dar NN, McLish O, et al
    Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers.
    Int J Mol Sci. 2024;25:849.
    PubMed         Abstract available

    Int J Surg Pathol

  50. CAO Q, Goldenberg M, Aron M, Wang T, et al
    Urinary Bladder "Melanosis": A Case Report and Review of the Literature.
    Int J Surg Pathol. 2024;32:104-108.
    PubMed         Abstract available

  51. PACHECO RR, Pacheco R, Cooley C, Kaufman R, et al
    Diffuse Carbonic Anhydrase 9 and GATA3 Expression in Fumarate Hydratase Deficient Renal Cell Carcinoma - A Case Report and Immunoprofile Review.
    Int J Surg Pathol. 2024;32:145-149.
    PubMed         Abstract available

    Int Urol Nephrol

  52. WANG S, Wei Z, Shu H, Xu Y, et al
    Early diagnosis and prognostic potential of RAC3 in bladder tumor.
    Int Urol Nephrol. 2024;56:475-482.
    PubMed         Abstract available

  53. BAHADORI A, Bray G, Rukin N
    Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
    Int Urol Nephrol. 2024;56:519-525.
    PubMed         Abstract available

  54. KACZMAREK K, Plage H, Furlano K, Hofbauer S, et al
    Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2024;56:499-508.
    PubMed         Abstract available

    J Biomol Struct Dyn

  55. LIU T, Ul-Haq W, Tang Q, Li W, et al
    Novel integrated Omics based computational approach for drug repurposing for non-muscle invasive bladder cancer (NMIBC).
    J Biomol Struct Dyn. 2024 Jan 21:1-11. doi: 10.1080/07391102.2024.2302343.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  56. TRIPATHI S, Bhirud DP, Singh M, Singh V, et al
    Early port site and peritoneal metastasis following robot-assisted radical cystectomy: a rare case report.
    J Cancer Res Clin Oncol. 2024;150:32.
    PubMed         Abstract available

    J Exp Clin Cancer Res

  57. WANG F, Zhang G, Xu T, Ma J, et al
    High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
    J Exp Clin Cancer Res. 2024;43:24.
    PubMed         Abstract available

    J Magn Reson Imaging

  58. GONG Y, Cheng Y, Zhang J, Bao ML, et al
    Role of Additional MRI-Based Morphologic Measurements on the Performance of VI-RADS for Muscle-Invasive Bladder Cancer.
    J Magn Reson Imaging. 2024 Jan 23. doi: 10.1002/jmri.29184.
    PubMed         Abstract available

    J Urol

  59. HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
    PubMed         Abstract available

    Medicine (Baltimore)

  60. XU S, Huang J
    Machine learning algorithms predicting bladder cancer associated with diabetes and hypertension: NHANES 2009 to 2018.
    Medicine (Baltimore). 2024;103:e36587.
    PubMed         Abstract available


  61. OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
    Metabolomic profiling of human bladder tissue extracts.
    Metabolomics. 2024;20:14.
    PubMed         Abstract available

    Nat Med

  62. GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
    Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Nat Med. 2024 Jan 19. doi: 10.1038/s41591-024-02814.


  63. JI J, Liu T, Yao Y, Liu W, et al
    Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
    Neoplasia. 2024;47:100961.
    PubMed         Abstract available

    Neurol Res

  64. ZHAO S, Li Y, Xu J, Shen L, et al
    APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Neurol Res. 2023 Nov 26:1-16. doi: 10.1080/01616412.2023.2287340.
    PubMed         Abstract available

    Nihon Hinyokika Gakkai Zasshi

  65. TANIGUCHI A, Hirakawa K, Mayama I
    Nihon Hinyokika Gakkai Zasshi. 2023;114:26-29.
    PubMed         Abstract available

  66. KITA S, Yamakawa M, Kono R, Soumiya K, et al
    Nihon Hinyokika Gakkai Zasshi. 2023;114:16-20.
    PubMed         Abstract available

    NPJ Precis Oncol

  67. FU S, Tan Z, Shi H, Chen J, et al
    Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
    NPJ Precis Oncol. 2024;8:14.
    PubMed         Abstract available

    Pathol Res Pract

  68. MOLLICA V, Tassinari E, Santoni M, Marchese PV, et al
    TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
    Pathol Res Pract. 2024;253:155008.
    PubMed         Abstract available

    Pilot Feasibility Stud

  69. PORSERUD A, Karlsson P, Nygren-Bonnier M, Aly M, et al
    The feasibility of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer, prior to the CanMoRe trial.
    Pilot Feasibility Stud. 2024;10:12.
    PubMed         Abstract available

    Sci Rep

  70. SU Z, You L, He Y, Chen J, et al
    Multi-omics reveals the role of ENO1 in bladder cancer and constructs an epithelial-related prognostic model to predict prognosis and efficacy.
    Sci Rep. 2024;14:2189.
    PubMed         Abstract available

  71. LU J, Hong H, Xiong Z, Zhang Y, et al
    Development and preliminary validation of a PROS scale for Chinese bladder cancer patients with abdominal stoma.
    Sci Rep. 2024;14:2187.
    PubMed         Abstract available

    Tunis Med

  72. OUANES Y, Chaker K, Yaich S, Foued D, et al
    Predictive factors of bladder tumor recurrence after radical treatment of upper urinary tract cancer.
    Tunis Med. 2023;101:356-361.
    PubMed         Abstract available

    Turk Patoloji Derg

  73. MOHAMED SHARAF R, Essam Eldin-Shibel P, Abd-El-Moeze NA
    Immunohistochemical Expression of Vitamin D Receptor (VDR) in Urinary Bladder Squamous Cell Carcinoma.
    Turk Patoloji Derg. 2024;1.
    PubMed         Abstract available

    Urol Int

  74. REIKE MJ, Reicherz A, Tully KH, Bahlburg H, et al
    An empirical survey on the adaption of neoadjuvant chemotherapy in bladder cancer.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536321.
    PubMed         Abstract available

    Urol Oncol

  75. KOPENHAFER L, Thompson A, Chang J, Sikirica S, et al
    Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey.
    Urol Oncol. 2024 Jan 24:S1078-1439(24)00015.
    PubMed         Abstract available

  76. RAMOS P, Mateus A, Manso M, Botelho F, et al
    Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
    Urol Oncol. 2024 Jan 23:S1078-1439(24)00010.
    PubMed         Abstract available

  77. MCFADDEN J, Tachibana I, Adra N, Collins K, et al
    Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.
    Urol Oncol. 2024 Jan 23:S1078-1439(23)00487.
    PubMed         Abstract available

    World J Urol

  78. ASHLEY S, Choudhury A, Hoskin P, Song Y, et al
    Radiotherapy in metastatic bladder cancer.
    World J Urol. 2024;42:47.
    PubMed         Abstract available

  79. TYSON MD
    Single incision robotic cystectomy and urinary diversion.
    World J Urol. 2024;42:45.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.